Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1

Pramod K. Mistry, Manisha Balwani, Hagit N. Baris, Hadhami Ben Turkia, T. Andrew Burrow, Joel Charrow, Gerald F. Cox, Sumita Danda, Marta Dragosky, Guillermo Drelichman, Amal El-Beshlawy, Cristina Fraga, Selena Freisens, Sebastiaan Gaemers, Evgueniy Hadjiev, Priya S. Kishnani, Elena Lukina, Pierre Maison-Blanche, Ana Maria Martins, Gregory PastoresMilan Petakov, M. Judith Peterschmitt, Hanna Rosenbaum, Barry Rosenbloom, Lisa H. Underhill, Timothy M. Cox*

*Corresponding author for this work

Research output: Contribution to journalLetter

Original languageEnglish (US)
Pages (from-to)101-102
Number of pages2
JournalBlood Cells, Molecules, and Diseases
Volume77
DOIs
StatePublished - Jul 2019

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Hematology
  • Cell Biology

Cite this

Mistry, P. K., Balwani, M., Baris, H. N., Turkia, H. B., Burrow, T. A., Charrow, J., Cox, G. F., Danda, S., Dragosky, M., Drelichman, G., El-Beshlawy, A., Fraga, C., Freisens, S., Gaemers, S., Hadjiev, E., Kishnani, P. S., Lukina, E., Maison-Blanche, P., Martins, A. M., ... Cox, T. M. (2019). Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1. Blood Cells, Molecules, and Diseases, 77, 101-102. https://doi.org/10.1016/j.bcmd.2019.04.003